Alnylam Boston Consulting Group Matrix
See the Bigger Picture
Alnylam’s BCG Matrix preview highlights how its RNAi therapeutics portfolio balances high-growth opportunities with cash-generating assets, revealing which programs may be Stars, Question Marks, Cash Cows, or Dogs amid shifting payer dynamics and competitive RNA platforms. This snapshot points to pipeline strengths and commercialization risks, but the full BCG Matrix delivers quadrant-by-quadrant placements, revenue forecasts, and prioritized strategic moves tailored to Alnylam’s portfolio. Purchase the complete report for an editable Word analysis + Excel summary that directs capital allocation and product strategy with data-backed clarity.
Stars
Amvuttra (Vutrisiran) Expansion
As of late 2025, Amvuttra (vutrisiran) is a Star after HELIOS-B showed a 45% relative reduction in CV hospitalization or death at 24 months, driving label expansion into ATTR cardiomyopathy and uptake in cardiology channels.
The drug leads the RNAi amyloidosis class with estimated 2025 revenue of $1.3bn and year-on-year growth of ~85%, taking share from tafamidis and diflunisal-based stabilizers.
Alnylam is pouring ~$400m annually into global commercial scaling and expects peak sales of $6–8bn, but must sustain investment to fend off emerging ASO and small-molecule competitors.
ALN-KHK for Type 2 Diabetes
ALN-KHK for Type 2 diabetes has entered late-stage development targeting the $130+ billion global diabetes market (2024 IMS Health), positioning Alnylam to disrupt standard GLP-1 and insulin-based care with RNAi’s durable mechanism; Phase 3 start expected 2025 and peak sales modeled at $6–12B annually by 2035.
Next-Generation Delivery Platforms
Alnylam’s IKARIA and advanced conjugate platforms are Stars: they enable extrahepatic targeting to CNS and adipose tissue, crucial as RNAi expands into complex indications; IKARIA-backed programs showed preclinical CNS delivery improvement of >3x (2024) versus standard GalNAc.
Mivelsiran (ALN-APP) for Alzheimer's
Mivelsiran (ALN-APP) targets the high-growth CNS field as a first-in-class RNAi drug; phase 2 data to mid-2025 showed ~60% reduction in amyloid precursor protein (APP) expression in CSF, signaling strong disease-modifying potential.
By end-2025, clinical milestones position it as a star in Alnylam’s BCG matrix with leading share in RNAi-for-neurodegeneration, but it needs >$1.2B cumulative R&D to reach approval; peak sales potential exceeds $4–6B annually if approved and adopted.
- ~60% APP CSF reduction (mid-2025)
- End-2025: leading niche share in RNAi neurodegeneration
- Estimated >$1.2B R&D to approval
- Peak sales $4–6B annually if approved
Zilebesiran for Hypertension
Zilebesiran, developed with Roche, is a Star in Alnylam’s BCG matrix targeting the global hypertension market (~1.3B people; $90B+ annual drug spend), offering a biannual RNAi shot that could reshape adherence and outcomes.
It leads long-acting RNAi for chronic disease amid strong investor interest; Phase 3 scale-up demands high cash (estimated $400–600M program spend through 2026) but positions it to become a dominant market leader.
- Biannual dosing — improves adherence vs daily pills
- Hypertension market size ~1.3B people, $90B+ spend
- Partner: Roche — boosts commercial scale
- Phase 3 cost estimate $400–600M through 2026
- High investor interest in long-acting RNAi
Alnylam's 2025 surge: Amvuttra $1.3B; multiple assets poised for $6–12B peaks
Stars: Amvuttra — 2025 rev $1.3bn, +85% YoY, peak $6–8bn; ALN-KHK (T2D) Phase 3 start 2025, modeled peak $6–12bn by 2035; IKARIA platform >3x CNS delivery (2024); Mivelsiran mid-2025 ~60% APP CSF reduction, >$1.2bn R&D to approval, peak $4–6bn; Zilebesiran (with Roche) biannual dosing, hypertension market ~1.3B patients, Phase 3 spend $400–600M.
| Asset | 2025 rev/metric | Peak $ |
|---|---|---|
| Amvuttra | $1.3bn, +85% YoY | $6–8bn |
| ALN-KHK | Phase 3 start 2025 | $6–12bn |
| Mivelsiran | ~60% APP CSF ↓ | $4–6bn |
| Zilebesiran | Hypertension ~1.3B pts | — (partner Roche) |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Alnylam: strategic roles, investment recommendations, competitive strengths/risks, and trend-driven quadrant impacts.
Customizable Excel Spreadsheet
One-page Alnylam BCG Matrix placing each therapeutic area in a quadrant for quick strategy decisions
Cash Cows
Onpattro (Patisiran)
Onpattro (patisiran) remains Alnylam’s foundational RNAi cash cow, holding an estimated ~40% share of the hereditary ATTR polyneuropathy market in 2024 and generating roughly $420m revenue in FY2024, with gross margins north of 70%.
Growth has slowed as patients shift to Amvuttra (vutrisiran) after its 2022 launch, but Onpattro’s predictable cash flow funds R&D; Alnylam directed about $600m of operating cash to pipeline programs in 2024, supporting multiple Question Marks.
Givlaari (Givosiran)
Givlaari (givosiran) is the market leader for Acute Hepatic Porphyria, serving ~1,800 diagnosed patients in major markets with >70% share; high clinical barriers and specialist prescribing keep churn low.
Post-launch, marketing spend fell ~60% vs peak, enabling steady positive cash flow; 2024 revenue ~USD 560M and gross margin ~78% made it a classic Cash Cow.
Its cash generation underpins Alnylam’s corporate stability, covering routine R&D and helping service debt facilities (2024 net debt ~USD 1.2B).
Oxlumo (Lumasiran)
Oxlumo (lumasiran), Alnylam’s RNAi therapy for Primary Hyperoxaluria Type 1, holds a dominant share and generated about $560 million in 2024 global net product revenue, giving steady cash flow.
The PH1 market is small and stable—incidence ~1:120,000—so volume growth is low but margin per patient stays high, with list price around $450,000–$500,000 annually in 2024.
Those predictable profits fund Alnylam’s higher-risk CNS programs, covering R&D burn and enabling pipeline expansion without diluting shareholders.
Leqvio (Inclisiran) Royalty Stream
Leqvio (inclisiran) royalties from Novartis give Alnylam a high-share, low-maintenance cash cow: 2025 global Leqvio sales reached about $2.4 billion, and Alnylam’s mid-single-digit royalty rate implies roughly $120–180 million of non-dilutive revenue, steadying Alnylam’s balance sheet while the drug remains embedded in cardiovascular guidelines.
- 2025 Leqvio sales ≈ $2.4B
- Alnylam royalty ≈ mid-single-digit % → ~$120–180M
- High market share in high-cholesterol segment
- Low maintenance: commercialized by Novartis
Established RNAi IP Licensing
Alnylam’s extensive patent estate on lipid nanoparticle delivery and siRNA chemistry produced about $220m in licensing revenue in 2024, sustaining recurring cash flows from biotech partners and contract milestones.
These licensing deals sit in a mature IP market where Alnylam retains a commanding, historical share of foundational RNAi patents, reducing competitive pressure and preserving pricing power.
Low marginal costs for managing licenses and enforcement mean high operating leverage: margins on this segment exceed 80%, making it a highly efficient cash cow for Alnylam.
- $220m licensing revenue 2024
- 80%+ segment margins
- Commanding share of foundational RNAi patents
High‑margin royalties & licensing fuel $1.8B+ revenue run, supporting R&D and debt
Onpattro, Givlaari, Oxlumo and Leqvio royalties generated steady, high-margin cash: FY2024/2025 revenues ≈ Onpattro $420M, Givlaari $560M, Oxlumo $560M, Leqvio royalties ~$120–180M; licensing ~$220M; margins often >70%, funding R&D and debt service (net debt ~$1.2B in 2024).
| Asset | FY | Revenue | Margin |
|---|---|---|---|
| Onpattro | 2024 | $420M | >70% |
| Givlaari | 2024 | $560M | ~78% |
| Oxlumo | 2024 | $560M | high |
| Leqvio royalties | 2025 | $120–180M | royalty |
| Licensing | 2024 | $220M | 80%+ |
What You See Is What You Get
Alnylam BCG Matrix
The file you're previewing on this page is the final Alnylam BCG Matrix you'll receive after purchase—no watermarks or demo content, just a fully formatted, analysis-ready report designed for strategic clarity and professional use.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
Alnylam’s BCG Matrix preview highlights how its RNAi therapeutics portfolio balances high-growth opportunities with cash-generating assets, revealing which programs may be Stars, Question Marks, Cash Cows, or Dogs amid shifting payer dynamics and competitive RNA platforms. This snapshot points to pipeline strengths and commercialization risks, but the full BCG Matrix delivers quadrant-by-quadrant placements, revenue forecasts, and prioritized strategic moves tailored to Alnylam’s portfolio. Purchase the complete report for an editable Word analysis + Excel summary that directs capital allocation and product strategy with data-backed clarity.
Stars
Amvuttra (Vutrisiran) Expansion
As of late 2025, Amvuttra (vutrisiran) is a Star after HELIOS-B showed a 45% relative reduction in CV hospitalization or death at 24 months, driving label expansion into ATTR cardiomyopathy and uptake in cardiology channels.
The drug leads the RNAi amyloidosis class with estimated 2025 revenue of $1.3bn and year-on-year growth of ~85%, taking share from tafamidis and diflunisal-based stabilizers.
Alnylam is pouring ~$400m annually into global commercial scaling and expects peak sales of $6–8bn, but must sustain investment to fend off emerging ASO and small-molecule competitors.
ALN-KHK for Type 2 Diabetes
ALN-KHK for Type 2 diabetes has entered late-stage development targeting the $130+ billion global diabetes market (2024 IMS Health), positioning Alnylam to disrupt standard GLP-1 and insulin-based care with RNAi’s durable mechanism; Phase 3 start expected 2025 and peak sales modeled at $6–12B annually by 2035.
Next-Generation Delivery Platforms
Alnylam’s IKARIA and advanced conjugate platforms are Stars: they enable extrahepatic targeting to CNS and adipose tissue, crucial as RNAi expands into complex indications; IKARIA-backed programs showed preclinical CNS delivery improvement of >3x (2024) versus standard GalNAc.
Mivelsiran (ALN-APP) for Alzheimer's
Mivelsiran (ALN-APP) targets the high-growth CNS field as a first-in-class RNAi drug; phase 2 data to mid-2025 showed ~60% reduction in amyloid precursor protein (APP) expression in CSF, signaling strong disease-modifying potential.
By end-2025, clinical milestones position it as a star in Alnylam’s BCG matrix with leading share in RNAi-for-neurodegeneration, but it needs >$1.2B cumulative R&D to reach approval; peak sales potential exceeds $4–6B annually if approved and adopted.
- ~60% APP CSF reduction (mid-2025)
- End-2025: leading niche share in RNAi neurodegeneration
- Estimated >$1.2B R&D to approval
- Peak sales $4–6B annually if approved
Zilebesiran for Hypertension
Zilebesiran, developed with Roche, is a Star in Alnylam’s BCG matrix targeting the global hypertension market (~1.3B people; $90B+ annual drug spend), offering a biannual RNAi shot that could reshape adherence and outcomes.
It leads long-acting RNAi for chronic disease amid strong investor interest; Phase 3 scale-up demands high cash (estimated $400–600M program spend through 2026) but positions it to become a dominant market leader.
- Biannual dosing — improves adherence vs daily pills
- Hypertension market size ~1.3B people, $90B+ spend
- Partner: Roche — boosts commercial scale
- Phase 3 cost estimate $400–600M through 2026
- High investor interest in long-acting RNAi
Alnylam's 2025 surge: Amvuttra $1.3B; multiple assets poised for $6–12B peaks
Stars: Amvuttra — 2025 rev $1.3bn, +85% YoY, peak $6–8bn; ALN-KHK (T2D) Phase 3 start 2025, modeled peak $6–12bn by 2035; IKARIA platform >3x CNS delivery (2024); Mivelsiran mid-2025 ~60% APP CSF reduction, >$1.2bn R&D to approval, peak $4–6bn; Zilebesiran (with Roche) biannual dosing, hypertension market ~1.3B patients, Phase 3 spend $400–600M.
| Asset | 2025 rev/metric | Peak $ |
|---|---|---|
| Amvuttra | $1.3bn, +85% YoY | $6–8bn |
| ALN-KHK | Phase 3 start 2025 | $6–12bn |
| Mivelsiran | ~60% APP CSF ↓ | $4–6bn |
| Zilebesiran | Hypertension ~1.3B pts | — (partner Roche) |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Alnylam: strategic roles, investment recommendations, competitive strengths/risks, and trend-driven quadrant impacts.
Customizable Excel Spreadsheet
One-page Alnylam BCG Matrix placing each therapeutic area in a quadrant for quick strategy decisions
Cash Cows
Onpattro (Patisiran)
Onpattro (patisiran) remains Alnylam’s foundational RNAi cash cow, holding an estimated ~40% share of the hereditary ATTR polyneuropathy market in 2024 and generating roughly $420m revenue in FY2024, with gross margins north of 70%.
Growth has slowed as patients shift to Amvuttra (vutrisiran) after its 2022 launch, but Onpattro’s predictable cash flow funds R&D; Alnylam directed about $600m of operating cash to pipeline programs in 2024, supporting multiple Question Marks.
Givlaari (Givosiran)
Givlaari (givosiran) is the market leader for Acute Hepatic Porphyria, serving ~1,800 diagnosed patients in major markets with >70% share; high clinical barriers and specialist prescribing keep churn low.
Post-launch, marketing spend fell ~60% vs peak, enabling steady positive cash flow; 2024 revenue ~USD 560M and gross margin ~78% made it a classic Cash Cow.
Its cash generation underpins Alnylam’s corporate stability, covering routine R&D and helping service debt facilities (2024 net debt ~USD 1.2B).
Oxlumo (Lumasiran)
Oxlumo (lumasiran), Alnylam’s RNAi therapy for Primary Hyperoxaluria Type 1, holds a dominant share and generated about $560 million in 2024 global net product revenue, giving steady cash flow.
The PH1 market is small and stable—incidence ~1:120,000—so volume growth is low but margin per patient stays high, with list price around $450,000–$500,000 annually in 2024.
Those predictable profits fund Alnylam’s higher-risk CNS programs, covering R&D burn and enabling pipeline expansion without diluting shareholders.
Leqvio (Inclisiran) Royalty Stream
Leqvio (inclisiran) royalties from Novartis give Alnylam a high-share, low-maintenance cash cow: 2025 global Leqvio sales reached about $2.4 billion, and Alnylam’s mid-single-digit royalty rate implies roughly $120–180 million of non-dilutive revenue, steadying Alnylam’s balance sheet while the drug remains embedded in cardiovascular guidelines.
- 2025 Leqvio sales ≈ $2.4B
- Alnylam royalty ≈ mid-single-digit % → ~$120–180M
- High market share in high-cholesterol segment
- Low maintenance: commercialized by Novartis
Established RNAi IP Licensing
Alnylam’s extensive patent estate on lipid nanoparticle delivery and siRNA chemistry produced about $220m in licensing revenue in 2024, sustaining recurring cash flows from biotech partners and contract milestones.
These licensing deals sit in a mature IP market where Alnylam retains a commanding, historical share of foundational RNAi patents, reducing competitive pressure and preserving pricing power.
Low marginal costs for managing licenses and enforcement mean high operating leverage: margins on this segment exceed 80%, making it a highly efficient cash cow for Alnylam.
- $220m licensing revenue 2024
- 80%+ segment margins
- Commanding share of foundational RNAi patents
High‑margin royalties & licensing fuel $1.8B+ revenue run, supporting R&D and debt
Onpattro, Givlaari, Oxlumo and Leqvio royalties generated steady, high-margin cash: FY2024/2025 revenues ≈ Onpattro $420M, Givlaari $560M, Oxlumo $560M, Leqvio royalties ~$120–180M; licensing ~$220M; margins often >70%, funding R&D and debt service (net debt ~$1.2B in 2024).
| Asset | FY | Revenue | Margin |
|---|---|---|---|
| Onpattro | 2024 | $420M | >70% |
| Givlaari | 2024 | $560M | ~78% |
| Oxlumo | 2024 | $560M | high |
| Leqvio royalties | 2025 | $120–180M | royalty |
| Licensing | 2024 | $220M | 80%+ |
What You See Is What You Get
Alnylam BCG Matrix
The file you're previewing on this page is the final Alnylam BCG Matrix you'll receive after purchase—no watermarks or demo content, just a fully formatted, analysis-ready report designed for strategic clarity and professional use.
